About Event

What Can You Expect at Japan’s Only Biomarker & Companion Diagnostics Summit?

As Japan’s precision medicine landscape continues to evolve and expand, the World Clinical Biomarkers & CDx Japan Summit will unite thought leaders and decision-makers, locally and globally, for unrivalled learning and networking opportunities.

Sharing data-driven updates on diagnostic technologies, case studies of successful CDx approval, and panel discussions to foster alignment between the US and Japan’s decision makers, this forum will empower stakeholders to accelerate precision therapies across various cancer indications.

Download the Agenda

Unmissable Event Highlights

Align International Strategy with Japan’s CDx Development Priorities

Harmonize companion diagnostics decision making across Japan, the US and beyond to ensure global clinical and regulatory alignment, with Pfizer, Eli Lilly & Bayer

Advance Biomarker Discovery & CDx Development with Innovative Technologies

Explore the potential of LBx testing, ctDNA, multi-omics, digital pathology, AI, and beyond, with data-driven content from the National Cancer Center Hospital East & FerreptoCure

Generate High Quality, Japan-Specific Clinical Data to Support Regulatory Approval

Strategize biomarker-driven clinical trials within Japan, discuss the PMDA’s decision-making, and understand how to streamline regulatory submissions with AstraZeneca, Takeda & TUV SUD

Streamline Market Access & Accelerate the Development of Precision Oncology Drugs

Develop robust CDx to ensure precision therapies reach the right patient populations at the right time, securing reimbursement to enable clinical implementation, with Astellas & MHLW